WOBURN, Mass., March 19 /PRNewswire/ -- AdvanDx announced it received Frost & Sullivan's 2008 Technology Innovation of the Year Award in the field of rapid in-vitro molecular diagnostic technology. The award recognizes how hospitals depend on AdvanDx's easy-to-use, molecular-based PNA FISH(TM) diagnostics to quickly identify bloodstream pathogens in hours instead of days. The rapid PNA FISH results enable laboratories to report critical information to physicians and pharmacists earlier to ensure optimal therapy and help reduce mortality rates for patients afflicted with bloodstream infections. 1,2
Frost & Sullivan's team of industry analysts conducted over 400 hours of analysis in the diagnostics market. "During the process of conducting the research, it became clear that AdvanDx would be a strong candidate to receive the in-vitro molecular diagnostic technology innovation of the year award," said Abhishek Dutta, Research Analyst, Frost & Sullivan. "PNA FISH is an extremely innovative technology platform that prevents the unnecessary use of drugs, enables doctors to make rapid diagnoses, treat patients sooner, save lives and significantly reduce costs throughout all areas of the hospital. As a result, AdvanDx is diversifying into new product lines that will enable the firm to explore new, multi-billion dollar in-vitro diagnostic markets," Dutta added.
"This Award further validates the impact of AdvanDx's molecular diagnostic products in the marketplace," said Thais T. Johansen, President and CEO of AdvanDx. "We appreciate that Frost & Sullivan has formally recognized the fundamental breakthrough value of our technology platform to provide clinicians with critical information as early as possible to help guide patient care, improve outcomes, and reduce hospital length-of-stay and costs. There are many diagnostic products, so it was particularly noteworthy that AdvanDx has been singled out for recognition," Johansen concluded.
Copyright©2008 PR Newswire.
All rights reserved